FDA Reinforces GCP Compliance Mandate for Foreign Clinical Trial Sites
- FDA leadership affirmed that Good Clinical Practice standards apply uniformly to all trial sites regardless of geography, and the agency will refuse to accept data from sites it cannot inspect or audit.
- Rising globalization of clinical research—including multi-regional trials with minimal U.S. patient enrollment—creates oversight and data-integrity risks that the FDA says it will address through stricter inspection access and transparency.
- Sponsors and CROs conducting foreign trials cannot assume lower FDA inspection probability; the agency is exploring public disclosure mechanisms for denied or conditioned inspection access.
Operational Impact
CROs managing foreign clinical trial sites must ensure full FDA inspection access and GCP documentation; failure to grant access or comply with audit requests may result in FDA rejection of trial data and marketing application denial.
Source: FDA What's New Drugs RSS